Long-term efficacy and safety of tofacitinib has been demonstrated in patients with active psoriatic arthritis, according to a final analysis of the OPAL Balance long-term extension study. The study, comprising 686 patients from 16 countries including Australia, found the proportion of patients with ACR20, ACR50, ACR70, and PsARC responses at 36 months was similar to ...
Long term data promising for tofacitinib in PsA: A/Prof Peter Nash
By Mardi Chapman
31 Mar 2021